We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Bladder Cancer

Journal Scan / Research · June 09, 2021

Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy

Clinical Genitourinary Cancer

 

Additional Info

Clinical Genitourinary Cancer
Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial
Clin Genitourin Cancer 2021 Apr 21;[EPub Ahead of Print], L Marandino, D Raggi, G Calareso, A Alessi, M Colecchia, A Martini, A Briganti, F Montorsi, R Madison, JS Ross, A Necchi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading